Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension

Figures & data

Figure 1 Effect of 8 weeks of treatment with telmisartan (T) 0 mg, 20 mg, 40 mg, and 80 mg plus amlodipine (A) 0 mg, 2.5 mg, 5 mg, and 10 mg on the change from baseline in the in-clinic seated trough (A) diastolic blood pressure (DBP) (mm Hg) or (B) systolic blood pressure (SBP) (mm Hg).

Notes: *P < 0.05 vs T monotherapy; ^†P < 0.05 vs A monotherapy. Data are least-squares mean (standard error) values adjusted for dosage, country/region, and baseline blood pressure.

Figure 2 Percentage of urinary albumin excretion rate (UAER) decrease with telmisartan–amlodipine combination at different doses.

Notes: ^{^}p <0.05, ^{^^}p <0.0001, ^ºp <0.03 ^ºp <0.01, ^ººp <0.001, Change from baseline; ^§p <0.05; ^§§p <0.01, ^§§§p <0.001, between treatment, ⁺p <0.05 vs 80/2.5.

Figure 3 Incidence of peripheral edema (%) in the amlodipine 10 mg (A10) group compared with combinations (telmisartan 40 mg [T40] or 80 mg [T80] plus amlodipine 5 mg [A5] or 10 mg).

Notes: *P < 0.05; **P < 0.0001 vs A10.